Journal ArticleDOI
Anand, Yusuf, Xie, et al. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulation and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217-227
Reads0
Chats0
About:
This article is published in Perspectives in Vascular Surgery and Endovascular Therapy.The article was published on 2008-11-25. It has received 25 citations till now. The article focuses on the topics: Warfarin.read more
Citations
More filters
Journal ArticleDOI
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Clive Kearon,Elie A. Akl,Anthony J. Comerota,Paolo Prandoni,Henri Bounameaux,Samuel Z. Goldhaber,Michael E. Nelson,Philip S. Wells,Michael K. Gould,Francesco Dentali,Mark Crowther,Susan R. Kahn +11 more
TL;DR: Strong recommendations apply to most patients, whereas weak recommendations are sensitive to differences among patients, including their preferences.
Journal ArticleDOI
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
Sidney C. Smith,Emelia J. Benjamin,Robert O. Bonow,Lynne T. Braun,Mark A. Creager,Barry A. Franklin,Raymond J. Gibbons,Scott M. Grundy,Loren F. Hiratzka,Daniel W. Jones,Donald M. Lloyd-Jones,Margo Minissian,Lori Mosca,Eric D. Peterson,Ralph L. Sacco,John A. Spertus,James H. Stein,Kathryn A. Taubert +17 more
TL;DR: In this article, the authors present the 2006 update of the American Heart Association (AHA)/American College of Cardiology Foundation (ACCF) guidelines on secondary prevention and provide evidence from clinical trials that further supports and broadens the merits of intensive risk-reduction therapies for secondary prevention.
Journal ArticleDOI
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
TL;DR: It is suggested that chronic myeloid leukemia heralds a fundamental shift in oncology toward effective but mostly noncurative long-term therapies and will require a proactive rational approach to minimize long- term cardiovascular and cardiometabolic toxicities.
Journal ArticleDOI
Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults
Connor A. Emdin,Simon G Anderson,Thomas Callender,Nathalie Conrad,Gholamreza Salimi-Khorshidi,Hamid Mohseni,Mark Woodward,Mark Woodward,Kazem Rahimi,Kazem Rahimi +9 more
TL;DR: Clinicians should be aware that those with established peripheral arterial disease are at an increased risk of a range of other vascular events, including chronic kidney disease, ischaemic heart disease, heart failure, atrial fibrillation, and stroke.
Journal ArticleDOI
Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice.
TL;DR: The thrombin inhibitor dabigatran reduces vascular oxidative stress and inflammation, improves endothelial function and decreases atherosclerosis in mice.
Related Papers (5)
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE).
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Deepak L. Bhatt,Keith A.A. Fox,Werner Hacke,Peter B. Berger,Henry R. Black,William E. Boden,Patrice Cacoub,Eric A. Cohen,Mark A. Creager,J. Donald Easton,Marcus Flather,Steven M. Haffner,Christian W. Hamm,Graeme J. Hankey,S. Claiborne Johnston,Koon Hou Mak,Jean-Louis Mas,Gilles Montalescot,Thomas A. Pearson,P. Gabriel Steg,Steven R. Steinhubl,Michael A. Weber,Danielle M. Brennan,Liz Fabry-Ribaudo,Joan E. Booth,Eric J. Topol +25 more